BioSpace News Archive

NeuroVive enrolls first subject in its European KL1333 phase Ia/b clinical study

Atlantic Healthcare plc announces the appointment of Andrew Jones as a non-executive director, bringing more than 25 years of international capital market experience in New York, London & Hong Kong to the Board Of Directors.

- Collaboration will combine Abbott’s leading continuous glucose monitoring (CGM) technology with Insulet’s Omnipod Horizon™ Automated Insulin Delivery System to offer an accurate, easy-to-use, integrated digital health platform - Integrated technology will provide people living with diabetes around the world an affordable, transformational experience for improved glucose control

– Part 2 efficacy portion of EnACT expected to commence Q1 2020 – BEDMINSTER, N.J., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that the independent Data Safety Monitoring Board (DSMB) for the EnACT study has completed its planned review of initial safety and tolerability data from the Part 1 dose escalation phase and unanimously approved proceeding with enrollment in the Part 2 efficacy phase at 2g of MAT2203 daily, the highest

NEW YORK, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chief Executive Officer, will present a corporate overview at two upcoming investor conferences: SVB Leerink 9 th Annual Global Healthcare Conference , on February 26, 2020 at 9:30 AM Eastern Time. The conference will be he

YARDLEY, Pa., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the appointment of Victor M. Clavelli as Chief Commercial Officer. Mr. Clavelli joins Optinose from Pfizer where, in the course of an accomplished 20-year career, he held leadership roles including marketing, sales, and regulatory affairs. Most recently, he served as the North American President f

BERKELEY HEIGHTS, N.J., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce fourth quarter and full year 2019 financial results on Wednesday, February 26, 2020. The Company will host a conference call and live webcast at 4:30 p.m. Eastern Daylight Time on the same day. Conference call information: US/Canada call:

NEWARK, Calif. , Feb. 19, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that Dinesh V. Patel , Ph.D., President and Chief Executive Officer, will present a corporate overview at the upcoming the SVB Leerink 9th Annual Global Healthcare Conference in New York . Presentation details: Event: SVB Leerink 9th Annual Global Healthcare Confere

SAN DIEGO, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics (the “Company”, NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases, today announced that Joseph Payne, Chief Executive Officer, will provide a corporate overview at the Cowen & Co. 40 th Annual Healthcare Conference, and the 32 nd Annual ROTH Conference. Cowen & Co. 40 th Annual Healthcare Conference Date:

Feb. 19, 2020 11:59 UTC Bristol-Myers Squibb to Hold Investor Day on April 2 NEW YORK--( BUSINESS WIRE )-- Bristol-Myers Squibb Company (NYSE: BMY) today announced that it will hold an Investor Day in New York City on Thursday, April 2, 2020. Giovanni Caforio, M.D. , chairman and chief executive officer, and members of the leadership team will discuss the Company’s strategy, pipeline and business opportunities. The event will be webcast simultaneously at http://investor.b